Discover what's new.

Access the latest news, business developments, company updates, industry trends, events and more.

| By Bill Kelly

Achillion schedules presentations on progress

Achillion Pharmaceuticals reports that Brian Di Donato, Chief Financial Officer, and Steven Zelenkofske, D.O., Chief Medical Officer, will present at the JMP Securities Life Sciences...

| By Bill Kelly

Artizan announces corporate progress and financing

Artizan Biosciences has announced corporate and financial updates: Artizan has completed its Series A funding, bringing the total raised to date to $12 million. Paul...

| By Bill Kelly

UConn looks at bioinformatics and bone health

A team of University of Connecticut researchers has received a $2.8 million grant from the National Institutes of Health for a five-year project studying how...

| By Bill Kelly

Help for Business in 2019 Connecticut Legislation

From the Rome Smith & Lutz team: The Connecticut General Assembly adjourned sine die the 2019 regular legislative session.  Governor Lamont will address the joint...

| By Kelley Gipson

Hamden biotech Vanessa advances in Turkey

Vanessa Research has been granted regulatory approval by the Turkish Ministry of Health to conduct a Phase II Clinical Trial for Shylicine®, an investigational oral...

| By Bill Kelly

SpringWorks gets fast track re neurofibromatosis

SpringWorks Therapeutics reports that the FDA has granted Fast Track designation for PD-0325901, an investigational, oral, small molecule inhibitor of MEK1 and MEK2, for the treatment...

| By Bill Kelly

Connecticut companies exhibit at BIO convention

Four New Haven-area companies exhibiting at Bio 2019, one the world’s largest forums for the biotech sector. More than 16,000 attendees are taking part in...

| By Bill Kelly

Intensity presents positive Phase 1/2 results

Intensity Therapeutics reports positive preliminary results from the company’s ongoing Phase 1/2 clinical trial of its lead product candidate, INT230-6, in a poster at the American...